Xeris Biopharma Holdings, Inc. (XERS) — SEC Filings
Xeris Biopharma Holdings, Inc. (XERS) — 24 SEC filings. Latest: 4 (May 1, 2026). Includes 11 8-K, 5 10-Q, 2 DEF 14A.
View Xeris Biopharma Holdings, Inc. on SEC EDGAR
Overview
Xeris Biopharma Holdings, Inc. (XERS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 1, 2025: Xeris Biopharma Holdings, Inc. filed an 8-K on December 1, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial transactions or material events were detailed in the provided excerpt.
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 1 bullish, 22 neutral, 1 mixed. The dominant filing sentiment for Xeris Biopharma Holdings, Inc. is neutral.
Filing Type Overview
Xeris Biopharma Holdings, Inc. (XERS) has filed 1 4, 11 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of XERS's 17 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $206.04M |
| Net Income | -$10.53M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $91.60M |
| Operating Margin | 3.94% |
| Total Assets | $370.19M |
| Total Debt | $219.47M |
Key Executives
- John P. Shannon
- Paul R. Edick
- Dr. Steven M. Paul
- Ms. Karen L. Smith
- Paul R. Kayser, Jr.
- Richard King
- Ashley L. Williams
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Xeris operates in a competitive landscape with companies developing novel drug delivery systems and therapies. Recent trends include a focus on specialty pharmaceuticals and innovative delivery mechanisms to improve patient adherence and outcomes.
Top Tags
sec-filing (3) · Pharmaceuticals (3) · executive-compensation (3) · governance (3) · Biopharma (2) · Revenue Growth (2) · corporate-governance (2) · financials (2) · 10-Q (2) · biopharma (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue (Q3 2025) | $74.38M | Increased from $54.27M in Q3 2024, a 37% increase. |
| Total Revenue (YTD 2025) | $206.04M | Increased from $142.97M in YTD 2024, a 44% increase. |
| Income from Operations (Q3 2025) | $6.73M | Improved from a loss of $12.89M in Q3 2024. |
| Income from Operations (YTD 2025) | $8.12M | Improved from a loss of $35.33M in YTD 2024. |
| Net Income (Q3 2025) | $621K | Improved from a net loss of $15.74M in Q3 2024. |
| Net Loss (YTD 2025) | $10.53M | Significantly reduced from a net loss of $49.72M in YTD 2024. |
| Accumulated Deficit | $682.4M | As of September 30, 2025, indicating historical losses. |
| Cash and Cash Equivalents | $91.60M | As of September 30, 2025, up from $71.62M at December 31, 2024. |
| Q2 2025 Product Revenue | $40.5M | Increased from $32.1M in Q2 2024, showing 26.2% growth. |
| Q2 2025 Total Revenue | $42.3M | Increased from $33.9M in Q2 2024, demonstrating 24.8% growth. |
| H1 2025 Product Revenue | $78.9M | Increased from $61.2M in H1 2024, indicating sustained growth. |
| H1 2025 Total Revenue | $82.5M | Increased from $64.8M in H1 2024, reflecting overall business expansion. |
| Product Revenue Growth (H1 2025 vs H1 2024) | 26.2% | Significant year-over-year growth in core product sales. |
| End of Reporting Period | 2025-03-31 | The 10-Q covers financial data up to this date. |
| Start of Reporting Period | 2025-01-01 | The 10-Q covers financial data from this date. |
Frequently Asked Questions
What are the latest SEC filings for Xeris Biopharma Holdings, Inc. (XERS)?
Xeris Biopharma Holdings, Inc. has 24 recent SEC filings from Jan 2024 to May 2026, including 11 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XERS filings?
Across 24 filings, the sentiment breakdown is: 1 bullish, 22 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Xeris Biopharma Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xeris Biopharma Holdings, Inc. (XERS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xeris Biopharma Holdings, Inc.?
Key financial highlights from Xeris Biopharma Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XERS?
The investment thesis for XERS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xeris Biopharma Holdings, Inc.?
Key executives identified across Xeris Biopharma Holdings, Inc.'s filings include John P. Shannon, Paul R. Edick, Dr. Steven M. Paul, Ms. Karen L. Smith, Paul R. Kayser, Jr. and 2 others.
What are the main risk factors for Xeris Biopharma Holdings, Inc. stock?
Of XERS's 17 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Xeris Biopharma Holdings, Inc.?
Forward guidance and predictions for Xeris Biopharma Holdings, Inc. are extracted from SEC filings as they are enriched.